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One of the hallmark features of glioblastoma multiforme (GBM), the most com-
mon adult primary brain tumor with a very dismal prognosis, is the accumulation of
CD4+CD25+Foxp3+ regulatory T cells (Tregs). Regulatory T cells (Tregs) segregate into
two primary categories: thymus-derived natural Tregs (nTregs) that develop from the inter-
action between immature T cells and thymic epithelial stromal cells, and inducible Tregs
(iTregs) that arise from the conversion of CD4+FoxP3− T cells into FoxP3 expressing cells.
Normally, these Treg subsets complement one another’s actions by maintaining tolerance
of self-antigens, thereby suppressing autoimmunity, while also enabling effective immune
responses toward non-self-antigens, thus promoting infectious protection. However,Tregs
have also been shown to be associated with the promotion of pathological outcomes,
including cancer. In the setting of GBM, nTregs appear to be primary players that contribute
to immunotherapeutic failure, ultimately leading to tumor progression. Several attempts
have been made to therapeutically target these cells with variable levels of success.
The blood brain barrier-crossing chemotherapeutics, temozolomide, and cyclophosphamide
(CTX), vaccination against theTreg transcriptional regulator, FoxP3, as well as mAbs against
Treg-associated cell surface molecules CD25, CTLA-4, and GITR are all different therapeutic
approaches under investigation. Contributing to the poor success of past approaches is the
expression of indoleamine 2,3-dioxygenase 1 (IDO), a tryptophan catabolizing enzyme over-
expressed in GBM, and critically involved in regulating tumor-infiltratingTreg levels. Herein,
we review the current literature on Tregs in brain cancer, providing a detailed phenotype,
causative mechanisms involved in their pathogenesis, and strategies that have been used
to target this population, therapeutically.
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MALIGNANT GLIOMA
Brain tumors fall into different classifications that depend on cel-
lular origin, histological characteristics (i.e., grade), as well as sub-
type. There are many central nervous system (CNS)-resident cells
including neurons, oligodendrocytes, and astrocytes that when
transformed, become neuroblastoma, oligodendroglioma, and
astrocytoma. Although all of these types of tumors are potentially
hazardous, here we focus on malignant glioma, with an emphasis
of astrocytoma grade IV [also known as glioblastoma multiforme
(GBM)], the most common primary adult brain tumor. GBM is
routinely associated with a poor prognosis. Even with an aggressive
treatment regimen that involves gross total resection when possi-
ble, followed by high dose irradiation and temozolomide (TMZ),
the median survival still remains at only 14.6 months (Stupp et al.,
2005). Although the annual incidence of GBM is only 3–5 cases
per 100,000 individuals, the anatomical localization within the
CNS combined with a selectively impermeable blood brain bar-
rier (BBB), results in a lack of many therapeutic agents from
entering the tumor effectively. However, today we have a consider-
ably more advanced understanding of the underlying pathogenic
mechanisms that lead to gliomagenesis. This rapidly evolving
understanding is informing the development of several different
therapeutic avenues for future treatment. Of these novel therapeu-
tic strategies, immunotherapy is one of the leading candidates for
creating durable and effective outcomes for patients. However, a
considerable challenge to developing effective GBM immunother-
apy is the complexity of the GBM microenvironment. Within the
stroma of the GBM is an intricate but poorly defined meshwork
of astrocytoma cells, microglia, astrocytes, pericytes, endothelial
cells, as well as many subtypes of leukocytes and hypoxia-induced
molecules that collectively contribute to a highly immunosuppres-
sive environment. Converting the glioma microenvironment from
one that is tolerant of GBM cells to one that supports immune-
mediated tumor rejection is considered to be one of the critical bar-
riers to achieving effective immunotherapy. Of the many immuno-
suppressive aspects intrinsic to GBM, CD4+CD25+FoxP3+ reg-
ulatory T cells (Treg) play a dominant role in deactivating pro-
ductive anti-GBM immune responses (El Andaloussi and Lesniak,
2006; El Andaloussi et al., 2006; Fecci et al., 2006a).
REGULATORY T CELLS
Regulatory T cells, which normally account for only 5–10%
of all circulating CD4+ T cells, are classically defined as cells
that possess the ability to suppress the proliferation of any
cytokine-secreting effector T cell [by down-regulating IL-2 and/or
interferon-gamma (IFN-γ) production]. Regulatory T cells con-
stitutively express the nuclear transcription factor, FoxP3, as
well as cell membrane-resident interleukin-2 receptor alpha
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[IL-2Rα (CD25)], cytotoxic T lymphocyte antigen-4 (CTLA-4),
glucocorticoid-induced tumor necrosis factor (TNF) receptor
(GITR), and TNF receptor superfamily member, OX40 (CD134).
Under normal physiological conditions, Treg function to main-
tain tolerance to both host and foreign antigens, resulting in the
inhibition of autoimmunity and contribution to the resolution of
productive effector T cell responses. In contrast, Treg deregulation,
either in the form of loss or gain of function, as well as the deple-
tion or accumulation of cells, contributes to autoimmune and
carcinogenic outcomes, respectively (Bennett et al., 2001; Curiel
et al., 2004).
The balance between the recruitment and functional state of
CD8+ cytotoxic T cells (Tc), CD4+ conventional T cells (Tconv),
and CD4+CD25+FoxP3+ regulatory T cells (Treg) is responsi-
ble for maintaining tolerance to self, while also responding to
pathogenic challenges arising from foreign bacteria and viruses
or endogenous stimuli in the form of cancer. An imbalance in this
carefully articulated balance can lead, and sometimes promote,
maladaptive reactions to both intrinsic and extrinsic pathogens.
This may take the form of autoimmunity, sepsis, chronic inflam-
mation, allergies/asthma, infection, or tumorigenesis. With regard
to the latter outcome, the collective action of Tc and Tconv is
thought to be overcome by malignancy-induced immunosuppres-
sion. Although there are many cellular players involved in sup-
pressing the effector immune response, the hyperactivation and
expansion of Treg appears to play a dominant role in inhibiting Tc
and Tconv through both cell-contact dependent and -independent
processes.
REGULATORY T CELL DIFFERENTIATION
Regulatory T cells are divided into two subsets based on origin:
natural Treg (nTreg) that develop in the thymus and inducible
Treg (iTreg) that arise by the induction of FoxP3 in CD4+FoxP3−
Tconv that have already gone through positive and negative selec-
tion in the thymus and emigrated into the periphery (Curotto
de Lafaille and Lafaille, 2009; Josefowicz and Rudensky, 2009;
Bilate and Lafaille, 2012). During thymic differentiation, Tc and
Tconv cell fate is regulated by T cell receptor (TCR) signal strength
and duration (Germain, 2002; Singer et al., 2008). Similarly, Treg
selection is mediated by a tightly controlled but poorly defined
range of TCR affinity and avidity, typically somewhere between
the level required for positive selection and the level needed to
delete self-reactive effector T cells. Utilizing transgenic mice that
possess a fixed TCR-β, direct sequence analysis has defined that the
Treg TCR repertoire is very diverse with minimal overlap of TCR
repertoire when compared to FoxP3− Tconv (Hsieh et al., 2004;
Pacholczyk et al., 2006). Importantly, retroviral transfer of Treg
vs. naïve CD4+ TCR-α libraries into RAG−/− TCR transgenic T
cells showed that the Treg TCR repertoire exhibits increased self-
reactivity, based on the ability of Treg TCR-expressing RAG−/− T
cells to expand and induce wasting disease in lymphopenic mice,
when compared to naïve CD4+ Tconv TCR-expressing RAG−/− T
cells. T cells retrovirally transduced with Treg TCR also proliferate
in vitro in response to autologous splenic antigen presenting cells
(APC) (as well as in response to invariant chain-deficient APC,
which primarily present endogenous protein-derived peptides that
are ubiquitously synthesized) in contrast to T cells transduced
with non-Treg TCR. Collectively, these data suggest that Treg TCR
recognize ubiquitously presented self-antigens (Hsieh et al., 2004).
Physiologically (i.e., in vivo), there is minimal TCR recognition
overlap between thymic-born and peripherally induced Foxp3+
cells, as well as when comparing peripherally induced FoxP3+ and
Foxp3− cells (Hsieh et al., 2006). In support of this suggestion
is data from a mouse model encoding a transgenic TCR-specific
for a pancreatic antigen showing that TCR-α chain utilization
from both thymic and peripheral Tconv was distinct from the
TCR-α chains isolated from Foxp3+ Treg (Wong et al., 2007).
Furthermore, in vitro-generated Treg with TCR stimulation com-
bined with TGF-β and IL-2 exposure, appear to be genetically
distinct from in vivo-isolated Treg from Foxp3-GFP mice, even
though a significant number of genes are shared by both Treg
subsets (Haribhai et al., 2011). Interestingly, this study also found
that both nTreg and iTreg are required for protection from lym-
phoproliferative disease, suggesting distinct but complementary
roles for the two Treg subsets. Collectively, these data indicate
that the majority of Treg are thymic in origin, with specific and
distinct requirements for iTreg generation and non-overlapping
immunosuppressive roles. A detailed comparison elucidating the
differences between nTreg and iTreg is listed in Table 1.
Although TCR signaling is required for Treg development, the
TCR signal, alone, is not sufficient for inducing FoxP3 expression
and downstream Treg lineage commitment. Interesting work has
Table 1 | Characteristics that distinguish nTreg from iTreg.
Characteristic NaturalTreg InducedTreg
Anatomical site of
maturation
Thymus Secondary lymphoid
organs/tissue sites
of inflammation
Co-stimulation CD28 and CTLA-4 CTLA-4
Cytokine
requirement
IL-2, TGF-β (?) TGF-β, IL-2, Retinoic
Acid
Transcription factors
required for
development
FoxP3 FoxP3, Ahr
Stability +++ +
TCR-specificity Self-antigens (primarily) Foreign antigens
(primarily)
General shared
markers
Foxp3, CD25, GITR, CTLA-4 Foxp3, CD25, GITR,
CTLA-4
Cell-specific markers Helios, Nrp1, PD-1, Swap70 Dapl1, Igfbp4
Mechanism of
suppression
Cell-contact dependent Cytokine-dependent
(?)
IL-6 can block
suppressor activity
Yes No
Hsieh et al. (2004), Horwitz et al. (2008), Quintana et al. (2008) Rubtsov et al.
(2010), Thornton et al. (2010) Bilate and Lafaille (2012), Verhagen et al. (2013).
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recently shown that expression of the TGF-β enhancer, CNS1, is
critical for the downstream commitment of iTreg, but not nTreg
(Samstein et al., 2012). The lack of iTreg led to increased fetal
resorption and placental leukocyte infiltration in allogeneic, but
not syngeneic hosts, further indicating a physiological comple-
mentarity of the nTreg and iTreg subsets. Moreover, while it has
been known for some time that CD28 plays a critical role in the
negative selection of Tconv and induction of FoxP3 in thymocytes,
recent work has now shown that CTLA-4 also plays a key role in
antigen specificity of both nTreg and Tconv (Verhagen et al., 2013).
Whether CTLA-4 plays a similar role in iTreg generation has yet to
be investigated.
Aside from the differences in nTreg and iTreg function and
development, critical differences exist in the regulation of FoxP3
between mice and humans (Ziegler, 2006). Human T cells express
two isoforms of FoxP3; the murine FoxP3 ortholog, as well as
a splice variant lacking exon 2 (Allan et al., 2005). Another dif-
ference in the regulation of Foxp3 expression between mice and
humans was found through analysis of stimulated CD4+CD25−
cells. Stimulation of human CD4+CD25- cells using CD3 and
CD28 mAbs results in the detectable expression of FoxP3 by
24 h, with a peak in FoxP3 expression at 72 h following the ini-
tial stimulus (Walker et al., 2003). In contrast, the CD4+CD25−
mouse cells do not result in the induction of FoxP3 expression
(Fontenot et al., 2003; Hori et al., 2003), suggesting that the tem-
porary induction of FoxP3 is linked to TCR stimulation, alone,
in human-, but not mouse-Treg. Another important consider-
ation is that the function of the thymus changes dramatically
over a similar period of time between mice and humans. In
mice, the naïve T cell pool is sustained throughout the lifetime of
the animal by continued thymic production, whereas in humans,
the naïve T cell pool is sustained almost entirely through T cell
division in the periphery due to the eventual involution of the
thymus in adulthood (de Braber, Immunity 2012). Thus, study-
ing the in vivo differences between nTreg and iTreg in mice may
not fully recapitulate the physiological characteristics relevant to
humans.
NATURAL AND INDUCED TREG SUBSETS IN CANCER
A consistent finding between previous studies demonstrates that
tumors recruit FoxP3+ Treg and that this accumulation tends to
be progressive, depending on tumor grade (El Andaloussi and
Lesniak, 2007; Quezada et al., 2011; deLeeuw et al., 2012; Sav-
age et al., 2013). For the majority of cancers, the accumulation of
Treg is associated with an impaired anti-tumor immune response
(Onizuka et al., 1999; Shimizu et al., 1999; Turk et al., 2004). In
these pre-clinical investigations, the elimination of CD25+ Treg
results in CD8+ T cell-mediated rejection of tumors from various
models. Whether tumor-infiltrating Treg are thymic or periph-
eral in origin remains a subject of open and active study. There
is ample evidence supporting the hypothesis that tumors con-
vert CD4+FoxP3− (Tconv) into CD4+FoxP3+ (iTreg) by tumor-
derived signals, while others suggest that nTregs are recruited
and/or expanded by the tumor (Nishikawa et al., 2003; Curiel et al.,
2004; Valzasina et al., 2006; Liu et al., 2007b; Hindley et al., 2011).
The roles of the two Treg subsets in cancer are not necessarily
mutually exclusive. In a study using a model of B cell lymphoma
and hemagglutinin, it was found that both nTreg and de novo-
produced iTreg combinatorially contribute to the Treg pool in the
context of a tumor (Zhou and Levitsky, 2007). Ultimately, the
ratio of nTreg to iTreg in a specific cancer may simply depend on
anatomical location, grade of tumor, and cellular origin. However,
determining this type of Treg may result in the ability to develop
more selective Treg-depleting therapies.
TREGS AND GLIOMA
Early work from our laboratory and independent groups iden-
tified a progressive increase in the numbers of CD25+FoxP3+
Treg with WHO grade II, III, and IV (GBM) astrocytoma, respec-
tively, either in the peripheral circulation or within the tumor of
human resected gliomas (Fecci et al., 2006a; El Andaloussi and
Lesniak, 2007; Heimberger et al., 2008a). Subsequent observations
found that thymus-derived nTreg, rather than glioma-induced
iTreg, represent the predominant population of CD4+FoxP3+ T
cells within brain tumors (Wainwright et al., 2011) (Figure 1).
Our group compared normal mice with brain tumors to those
FIGURE 1 | A model depicting the development, maturation and
recruitment of regulatoryT cells (Treg) in glioma-bearing hosts.
Thymus-derived (natural) nTreg are the predominant resident in glioma,
when compared to the tumor-induced iTreg. Although both Treg subsets
express FoxP3, these subsets respond to different classes of antigens and
possess different epigenetic stability with regard to FoxP3-regulated
immunosuppressive control and cytokine function. Moreover, nTreg
primarily recognize self-antigens, while iTreg predominantly recognize
tumor-associated antigens that are not normally endogenously expressed.
Upon infiltration and/or expansion in(to) the glioma, Treg promote tumor
formation by suppressing CD8+ cytotoxic T cell-mediated tumor rejection.
(Floess et al., 2007; Thornton et al., 2010; Wainwright et al., 2011).
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that had been previously thymectomized, with or without admin-
istration of the Treg-depleting CD25 mAb. Thymectomy, alone,
resulted in a significant decrease of tumor-infiltrating Treg, sup-
porting the hypothesis that glioma is predominantly infiltrated
by thymus-derived Treg. Furthermore, combining thymectomy
with CD25 mAb further decreased tumor-infiltrating Treg levels,
although this was not statistically significant from the thymectomy
alone group. In support of these data, we reported the expres-
sion of Helios, an Ikaros-family transcription factor shown to be
expressed exclusively by nTreg and not iTreg (Thornton et al.,
2010), to be expressed by ∼90% of all brain tumor-resident Treg.
To confirm that this finding was not specific to mice, we also
showed that Helios+ Tregs predominate in human GBM as well.
Our finding that nTreg are the predominant Treg subtype in brain
tumors has recently been supported in other cancer models using
updated and refined methodology of detection (Hindley et al.,
2011; Malchow et al., 2013). Therapeutically, these results imply
that future Treg-depleting strategies by targeting nTreg based on
their unique antigen-specific TCR repertoire may be more selec-
tive and therefore (potentially) possess fewer side-effects. This
relies on the hypothesis that nTreg depletion is associated with
more effective anti-glioma effector response coincident with a
greater survival advantage, which is now the suggested dogma
(El Andaloussi et al., 2006; Grauer et al., 2008; Banissi et al., 2009;
Maes et al., 2009; Wainwright et al., 2011).
Independent of the importance related to Treg origin is the find-
ing that soluble factors originating from GBM promote the in vitro
expansion of Tregs while simultaneously inducing the expression
of pro-apoptotic genes in Tconv (Crane et al., 2012). The pres-
ence of tumor cell-conditioned medium also causes conventional
CD4+ T cells to transiently upregulate the expression of Foxp3
and TGF-β. Interestingly, 10 days of co-culturing CD4+ T cells in
GBM-conditioned media was long enough to return TGF-β and
FoxP3 levels to a similar level found in Tconv. This temporary
induction of the Treg phenotype in Tconv, in vitro, is in line with
our in vivo finding that brain tumor-infiltrating Tregs are primarily
thymus-derived, rather than converted from a Tconv population.
TREG TRAFFICKING TO GBM
Chemotaxis of leukocytes occurs, in part, through the interac-
tion of chemokines interacting with cognate chemokine receptors.
This interaction represents a highly promiscuous relationship and
reflects the interaction between many different chemokine recep-
tors that possess redundant roles for recognizing multiple cognate
chemokines (Mailloux andYoung,2010; Zlotnik andYoshie,2012).
Once such interaction is between the chemokine, CCL22, and its
cognate chemokine receptor, CCR4, which is expressed on Tregs
and has been implicated in Treg recruitment to tumors using mul-
tiple models (Curiel et al., 2004; Miller et al., 2006; Jacobs et al.,
2010). In glioma,∼74% of Treg isolated from the peripheral blood
of GBM patients express CCR4, which is significantly increased
when compared to the∼43% of Treg expressing CCR4 in healthy
(control) patients (Jordan et al., 2008). These data suggest that
some soluble factor(s) originating from the GBM primes Treg to
induce or upregulate CCR4. Coincidently, GBM-resected speci-
mens have previously been shown to produce CCL2 and CCL22,
both of which are chemokines that attract CCR4-expressing Treg
(Sebastiani et al., 2001; Jordan et al., 2008). These findings collec-
tively suggest that one novel strategy for therapeutic intervention
may involve the inhibition of Treg trafficking to the GBM, as
has been shown to be an effective approach in other models of
cancer (Pere et al., 2011). However, to determine the physiolog-
ical significance of inhibiting the CCL22-CCR4 axis in human
GBM, it may be prudent to first test this as a proof-of-concept
in mouse GBM models, which has yet to be performed. Critical
points to address in these pre-clinical studies include the degree of
redundancy between Treg-recruiting chemokines, whether selec-
tive chemokine blockade unintentionally disrupts Tc and Tconv
homing to the glioma, as well as the clinically relevant consider-
ation: how chemokine neutralization affects the Treg population
already within the tumor bed.
TGFβ, TREGS, AND GLIOMA
TGF-β production by glioma represents a complex aspect regu-
lating Tregs in brain tumors. Since glioma expresses high levels
of select TGF-β isoforms, combined with the role of TGF-β in
converting Tregs in vitro, one might expect an increased level
of iTreg in brain tumors (Kaminska et al., 2013). However, one
possible explanation for the finding that most Treg are thymus-
derived (Wainwright et al., 2011), is the contribution of the stroma
in determining whether Treg are recruited rather than converted
from Tconv. Given the microenvironment of the brain, including
the unique contribution of the BBB, unique mode of lymphatic
drainage and highly immunosuppressive environment, even under
normal conditions, the mechanisms regulating Treg accumulation
in brain tumors may be independent of the TGF-β signaling path-
way. However, it is important to note that TGF-β neutralization
leads to a decrease in the level of brain tumor-infiltrating Tregs
(Ueda et al., 2009) suggesting that this cytokine somehow plays a
role in Treg recruitment and/or expansion.
REGULATORY T CELLS AND ANTIGEN SPECIFICITY
The antigen specificity of tumor-infiltrating Tregs is a complex
issue and is under current investigation by many laboratories,
including our own. Since nTreg primarily recognize self-antigens,
whereas iTreg most frequently recognize foreign antigens, the
question of which antigens are being recognized by tumor-
infiltrating Treg is important, given that nTreg appear to dominate
in many tumor environments; including GBM. Moreover, the
enrichment of nTreg may reflect an insufficient level of TCR stim-
ulation required for peripheral Treg induction in response to “for-
eign” antigens. It is also possible that iTreg promoting cytokines
are not present at the requisite levels in the tumor microenviron-
ment (Savage et al., 2013). Although the identification of a Treg
antigen in the context of malignancy remains to be a challenging
task, a central question regarding tumor-infiltrating nTreg anti-
gen specificity has recently been addressed. In a recent study by
Malchow et al. (2013), a single TCR (designated MJ23) was found
to be over-represented in the tumor-infiltrating Treg population
using a transgenic mouse model of prostate cancer. Interestingly,
the identified TCR was specific to an antigen expressed in nor-
mal prostate tissue. After generating a mouse with the transgenic
MJ23 TCR, the authors demonstrated that it was sufficient to drive
Treg development in the thymus in an Aire-dependent manner.
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These results have important implications for Treg antigen speci-
ficity in glioma. Since a majority of Treg in the GBM are nTreg,
these GBM-infiltrating Treg may recognize self-antigens that are
derived from the CNS. However, whether this paradigm holds
true in experimental GBM models and in patients remains a tan-
talizing consideration for further study. Ultimately, investigating
the antigen specificity of Treg in glioma is a way to increase our
understanding of Treg biology for the design of selective thera-
peutic strategies to counter Treg-induced immunosuppression in
brain tumors.
TRYPTOPHAN CATABOLISM AND BRAIN TUMORS
Indoleamine 2,3-dioxygenase 1 (IDO) is the rate-limiting enzyme
that mediates catabolism of the essential amino acid, tryptophan,
to downstream catabolites leading to end products of picolinic
acid and NAD+, as well as CO2 and ATP (Figure 2). Addi-
tional enzymes that have a tryptophan catabolizing capability
include indoleamine 2,3-dioxygenase 2 (IDO2) and tryptophan
2,3-dioxygenase (TDO). Notably, TDO has recently been high-
lighted to have an association between upregulated expression
in patient glioma specimens and an overall decrease in survival
(Opitz et al., 2011). However, here we focus on the function of
IDO, its relevance in cancer and inflammation and how it regulates
Treg in GBM.
IDO AND TRYPTOPHAN CATABOLISM
Indoleamine 2,3-dioxygenase 1 was first identified to be involved
in tryptophan catabolism in 1975 by a group that provided the
first evidence of catalytic activity and biological function (Hayaishi
et al., 1975; Hirata et al., 1975). Shortly therein, the group identi-
fied superoxide anions to be a critical component required for IDO
activity (Taniguchi et al., 1977) and that Fe2+ was also required
for this complex assembly (Hirata et al., 1977). By 1978, it was
suggested that IDO was associated with inflammatory processes,
since it was induced upon the exposure of mice to E. Coli-derived
lipopolysaccharide in the lungs of mice (Hayaishi and Yoshida,
1978; Yoshida and Hayaishi, 1978). Importantly, this mecha-
nism possessed a quick turnover based on a peak in tryptophan
catabolism at ∼24 h and decreasing back to baseline by 6 days
post-treatment. Collectively, these data demonstrated IDO to be
induced by inflammation, superoxide anion-dependent, and pos-
sessing both a heme group and catalytic activity for the pyrrole
ring of indoleamine-containing compounds.
INTERACTION BETWEEN IDO, LEUKOCYTES, AND TUMOR
CELLS
Several pro-inflammatory factors have been identified that induce
IDO expression in human peripheral blood cells including IFN-α,
IFN-β, IFN-γ, and LPS (Carlin et al., 1987, 1989); although other
individual and combinatorial pro-inflammatory agents are capa-
ble of regulating IDO expression and activity as well. At approx-
imately the same time, it was found that lung cancer patients
bearing malignant tumors had a 20-fold higher level of IDO,
when compared to patients bearing benign lesions (Yasui et al.,
1986). In vitro exposure of lung slices to IFN-γ further demon-
strated that this cytokine played a critical role in the induction of
IDO; although IFN-α was also capable of inducing IDO expres-
sion, albeit less potently. Interestingly, early experiments analyzing
FIGURE 2 | Schematic representation of l-Tryptophan consumption in
the body. l-tryptophan is an essential amino acid that is utilized during
protein synthesis. In the presence of tryptophan hydroxylase and the
co-factor, iron (not shown), l-tryptophan is converted to the
neurotransmitter, serotonin. However, in the presence of indoleamine
2,3-dioxygenase 1 (IDO), l-tryptophan is converted to l-kynurenine.
l-kynurenine can then be converted to kynurenic acid, 3-hydroxykynurenine,
or anthranilic acid via kynurenine aminotransferase (KAT), kynurenine
3-monooxygenase (KMO), and kynureninase [KYNU (also known as
l-kynurenine hydrolase)], respectively. 3-hydroxyanthranilic acid is converted
by 3-hydroxyanthranilic acid oxygenase (not shown) to
2-amino-3-carboxymuconate-6-semialdehyde. This downstream catabolite
can further be catabolized to the final metabolic products of picolinic acid
via picolinic carboxylase [also known as
2-amino-3-carboxymuconate-6-semialdehyde-dacarboxylase (ACMSD)],
quinolinic acid through a non-enzymatic process or glutaryl CoA through a
series of oxido-reductive reactions.
the allogeneic anti-tumor immune response found that IDO was
induced in tumor cells when injected into an allogeneic-, but
not syngeneic-hosts (Yoshida et al., 1988). When allogeneic and
syngeneic cells were mixed and then injected, intraperitoneally
(i.p.), the induction of IDO occurred in both cell types, suggest-
ing a global inflammatory promoter (such as IFN-γ). However,
it is important to note that only the allogeneic cells were rejected
under these conditions and not syngeneic cells, even though both
cell types were infiltrated by mononuclear cells (Yoshida et al.,
1988). Thus, IDO induction appeared to be regulated by pro-
inflammatory factors and is involved the anti-tumor immune
response.
In 1995, IFN-γ-induced IDO activity was demonstrated in
three different types of ovarian xenografts in nude mice that
lack endogenous T cells (Burke et al., 1995). In all three tumor
models, l-tryptophan was significantly depleted, commensurate
with the presence of l-kynurenine, which was also found in the
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surrounding tissues. Interestingly, in situ hybridization demon-
strated IDO expression in all areas of the tumor, not just in
the surrounding peripheral cells. Also notable was that IDO
expression remained elevated in tumor cells, even when tryp-
tophan levels had already returned to normal levels, suggesting
some level of post-transcriptional regulation of the expression.
By the year 2000, a correlation between IDO-expressing den-
dritic cells and T cell function was established (Hwu et al.,
2000). It was found that both CD40L and T cell-expressed IFN-γ
could regulate IDO expression by in vitro-cultured DCs. Func-
tionally, the impairment in T cell proliferation induced by DC-
expressed IDO could be reversed when 1-dl-methyltryptophan
(1-MT), a pharmacological inhibitor of IDO, was added to
the DC-T cell co-cultures. Further studies showed that IL-6
played a critical role in reversing the tolerogenic functions of
in vitro-cultured CD8+ tolerogenic DCs by decreasing IFN-γ
receptor and that this activity was correlated to the decreased
ability for tryptophan degradation (Grohmann et al., 2001).
Shortly thereafter, it was shown that mice pre-immunized with
IDO-transfected cells could significantly inhibit the allogeneic
T cell response in adoptively transferred cells (Mellor et al.,
2002).
INHIBITION OF IDO AS A POTENTIAL TUMOR THERAPY
The first evidence that inhibiting IDO could be utilized as a ther-
apeutic modality against tumors came in 2002, when Friberg
et al. (2002) showed that mice bearing Lewis lung carcinoma and
administered 1-MT demonstrated slower tumor growth, when
compared to mice not administered the IDO inhibitor. Further
evidence showed that many different types of human tumors
express high levels of IDO expression including 100% of prosta-
tic, colorectal, pancreatic, cervical, and endometrial carcinomas,
with 90% of GBM specimens expressing variable levels of IDO
(Uyttenhove et al., 2003). It was also demonstrated that pre-
immunized mice were unable to reject tumors that were IDO+,
suggesting that IDO overrides the anti-tumor immune response.
This effect could be partly reversed when the pre-immunized mice
were co-administered 1-MT.
Independent of tumor-derived IDO, it has been shown in
mouse models that DC residing in tumor-draining lymph nodes
also possess potently immunosuppressive properties (Munn et al.,
2004) which include the activation of mature Treg (Sharma et al.,
2007). Functionally, these plasmacytoid DCs (pDC) are rendered
ineffective when genetically deficient for- or pharmacologically
inhibited for-IDO activity, strongly suggesting that IDO is a crit-
ical requirement for the immunosuppression induced in pDC.
Independent support for this hypothesis was demonstrated when
investigators showed that the CD200 engagement with CD200R
on pDC induces and/or regulates IDO expression (Fallarino
et al., 2004). However, the relationship between CD200 expres-
sion in tumor-draining lymph nodes has yet to be established.
In vitro-based work has also identified a 2-step requirement for
induction and enzymatic activation of IDO in DC (Braun et al.,
2005). The induction step requires exposure to prostaglandin E2
(PGE2), while the activation step requires signaling through either
the tumor necrosis factor receptor or a toll-like receptor ago-
nist. These data may be particularly relevant when considering
DC-based immunotherapy protocols, since limiting IDO expres-
sion would be a desirable characteristic for maximal therapeutic
efficacy.
Although 1-MT has long been used as a potent inhibitor of IDO
enzymatic activity, the search for other, potentially more effec-
tive and/or combinatorially applied agents continues. Accordingly,
3-(4-morpholinyl)sydnonimine, a peroxynitrite generator, signif-
icantly inhibits IDO activity without affecting expression levels
(Fujigaki et al., 2006). Specifically, nitration of Tyr15 was the most
important factor related to inhibiting IDO activity. In a separate
in vitro study, H2O2 showed potent inhibitory properties against
IDO activity by oxidation of cysteine residues to sulfinic and sul-
fonic acids (Poljak et al., 2006). Intriguingly, celecoxib, a cyclooxy-
genase 2 inhibitor has been shown to decrease the expression of
IDO in a spontaneous mammary gland tumor model, in vivo (Basu
et al., 2006). With regard to the various IDO inhibitors, tonic reg-
ulation of IDO expression and inhibition is likely to depend on
dosage of the agent. One example of this is the demethylating drug,
Zebularine. At low-doses, Zebularine increases the immunogenic-
ity of tumor cells, while high doses decreases immunogenicity;
the latter of which is dependent on increased IDO expression
(Liu et al., 2007a). From an immunotherapeutic perspective, it
would be desirable to increase the immunogenicity of tumors to
increase the likelihood of antigen-specific Tc-mediated tumor cell
killing. Finally, it is important to note that stereoisomers of differ-
ent compounds may possess greatly different effects in future IDO
inhibitory strategies. For example, 1-MT is found as 2 stereoiso-
mers; levorotary (L) and dextrorotary (D). Importantly, while
L1-MT appears to significantly inhibit IDO1 activity, D1-MT is
a relatively inefficient inhibitor of IDO1 and rather, appears to
effectively inhibit IDO2 (Lob et al., 2009). This highlights how
subtleties in enzymatic modulation can vary widely using virtu-
ally identical compounds, while also raising questions as to why
D1-MT appears to play a stronger immunotherapeutic role, when
compared to the actions of L1-MT (Hou et al., 2007).
IDO, TREGS, AND GLIOMA
Early work in human astrocytes demonstrated that these cells are
very sensitive to the effects of IFN-γ by upregulating the enzyme,
IDO and the production of NAD (Grant et al., 2000). Further
studies showed that IFN-γ also stimulated IDO expression in
transformed astrocytes in vitro (Grant and Kapoor, 2003; Miyazaki
et al., 2009) and in vivo (Uyttenhove et al., 2003). Although
this potent IFN-induced IDO expression may play a protective
anti-viral role under certain conditions (Adams et al., 2004), it
also appears to play a maladaptive role in the context of brain
cancer.
Recent work from our laboratory has demonstrated that the
upregulation of IDO mRNA in resected glioma specimens is asso-
ciated with a significant decrease of overall survival in patients
with glioma (Wainwright et al., 2012). This correlation between
increased IDO and decreased survival has been confirmed at the
protein level, independently (Mitsuka et al., 2013). Our investi-
gation found that the expression of IDO by brain tumor cells,
rather than peripheral cells (i.e., astrocytes, microglia, pDC, etc.),
mediated tumorigenesis. This was supported by the finding that
IDO-competent tumors accumulate immunosuppressive Tregs
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in both IDO-competent and -deficient mice (Wainwright et al.,
2012). In contrast, IDO-deficient tumors fail to support sig-
nificant Treg expansion in both IDO-competent and -deficient
mice. Importantly, the IDO-regulated Treg expansion was asso-
ciated with a significant decrease in overall survival, when com-
pared to mice bearing IDO-deficient brain tumors. Notably, the
beneficial effect on survival was not solely due to the lack of
Treg recruitment to the glioma since mice lacking any major
T cell subset (i.e., Tc and/or Tconv) failed to support long-
term survival, even in the absence of IDO expression by brain
tumors.
The IDO-mediated Treg accumulation in brain tumors pre-
dominantly reflects an expansion of thymus-derived, rather than
tumor-induced Tregs (Wainwright et al., 2011). This implies that
one of the primary effects of IDO is to induce and/or increase
the chemokines that attract Tregs. Supporting this hypothesis is
the finding that IDO+, but not IDO− DCs express the Treg-
recruiting chemokine,CCL22 (Onodera et al., 2009). Coincidently,
GBM cells resected from patients have been shown to express the
chemokine, CCL22 (Jordan et al., 2008). Whether IDO expres-
sion directly mediates the upregulation of CCL22 in GBM cells
has yet to be determined. Since the principal function of IDO
is suggested to be enzymatic in nature, it is possible that IDO
catabolizes tryptophan to kynurenine and that a downstream
kynurenine catabolite acts as a co-factor to increase CCL22. This
may occur through the recently discovered interaction between
kynurenine and aryl hydrocarbon receptor (Ahr) (Mezrich et al.,
2010), based on previous data showing that Ahr cooperates with
RelB to affect chemokine production (Vogel et al., 2007a,b,c).
Although CCL22 was not analyzed in these studies, the potential
effect of Ahr on CCL22 transcription is likely to be contextual
and therefore, dependent on multiple factors from the tumor
microenvironment.
The complexity of IDO signaling may allow it to directly acti-
vate CCL22 transcription through a slightly different mechanism
in addition to the one described above. Recent work has now
shown that aside from the enzymatic function of IDO, there is
a distinct signaling component due to the interaction of IDO
with TGF-β-induced SHP1 and SHP2 (Pallotta et al., 2011). The
interaction leads to the phosphorylation of IKKα and the release
of RelB, nuclear translocation and subsequent downstream tran-
scriptional effects. In the context of a brain tumor, it is therefore
possible that the TGF-β-induced SHP proteins interact with IFN-
γ-induced IDO, resulting in the release of RelB, interaction with
Ahr and downstream effects that include the activation of CCL22
transcription (Figure 3). However, this hypothesis remains to be
tested.
THERAPEUTIC TARGETING OF TREGS
Given the pathogenic role that Treg mediate in the context of
malignant brain tumors, an obvious therapeutic direction is their
selective depletion from both the tumor microenvironment and/or
secondary lymphoid tissues, where Tc and Tconv priming and
effector function is affected. This highly translational research arm
is a very active and dynamic field, with the goal of determining
which monotherapy and/or combinatorial therapy will lead to
the greatest impact on decreasing Treg numbers and/or function.
FIGURE 3 | A theoretical model depicting the process of regulatoryT
cell (Treg) recruitment and expansion in brain tumors. The interaction of
Treg with cervical (draining) lymph node (cLN)-resident dendritic cells (DC)
through the T cell receptor (TCR)-peptide/major histocompatibility complex
(MHC) II activates and epigenetically stabilizes the expression of
CCR4-expressing Treg. These recently stimulated Treg then emigrate from
the cLN into the circulation where they can respond to the gradient of the
Treg-recruiting chemokine, CCL22, being produced by the glioma. Within
the glioma, innate natural killer (NK) cells that initially respond to the tissue
disruption and inflammatory signals produced by the tumor are later joined
by antigen-specific CD8+ cytotoxic T cells (Tc); both of which produce the
pro-inflammatory cytokine, interferon-gamma (IFN-γ). This cytokine acts on
the glioma-expressed, IFN-γR, resulting in downstream Janus-kinase/signal
transducer and activator of transcription (JAK/STAT) activity that
subsequently induces indoleamine 2,3-dioxygenase 1 (IDO). IDO mediates
the enzymatic conversion of l-tryptophan to l-kynurenine. The latter
metabolite interacts with the cytoplasmically localized, aryl hydrocarbon
(AHR). This interaction drives the localization of this hormone-like receptor
into the nucleus. Simultaneously, TGF-β signaling (via glioma-expressed
TGF-βR engagement) drives SMAD-induced IKK-α phosphorylation, leading
to p52 (RelB) nuclear translocation. Nuclear Ahr and p52 interact, leading to
a unique transcriptional response further driving IDO expression (not
shown), as well as CCL22 and TGF-β chemokine and cytokine expression,
respectively. Independently, and due to the permeable nature of the
downstream catabolite, l-kynurenine, Treg proliferation occurs. However,
while many components of this paradigm have been shown to occur in
disparate cell types, the comprehensive scheme proposed has yet to be
shown in glioma, specifically. (Hotfilder et al., 2000; Vogel et al., 2007b,c;
Jordan et al., 2008; Mezrich et al., 2010; Opitz et al., 2011; Pallotta et al.,
2011; Wainwright et al., 2011, 2012).
Below, we highlight some of the most prescient targets leading
to the disruption of Treg function and/or depletion (Figure 4).
However, it should be noted that in addition to those therapeutic
agents and targets described below, far more effective and specific
methods are currently being developed.
TEMOZOLOMIDE
Temozolomide, a second generation DNA alkylating agent, methy-
lates the O6 position of guanine causing double stranded DNA
cross-linking. The DNA damage results in calcium-dependent
apoptosis and autophagy, eventually leading to cell death. TMZ
is also reported to activate p53 and p21WAF1/Cip1-mediated G2/M
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FIGURE 4 | Possible modes of therapeuticTreg neutralization for the
treatment of glioblastoma multiforme (GBM). (A) Low-dose
administration of the chemotherapeutic agents, temozolomide (TMZ), and
cyclophosphamide (CTX), have been shown to have a beneficial impact on
Treg levels in both patients and animal models of GBM. (B) Targeting
constitutively expressed receptors on the cell surface of Treg is another way
that has demonstrated variable levels of success. IL-2Rα (CD25) targeting
with monoclonal antibodies neutralizes and/or depletes Treg, in vivo.
Similarly, agonistic GITR mAb leads to inhibition of Treg suppressor
capability and loss of tumor-homing capacity. In contrast, CTLA-4 mAb
appears to inhibit the Treg-mediated induction of indoleamine
2,3-dioxygenase 1 (IDO) in dendritic cells (DC), as well as possesses
independent effects on effector T cells. (C) Neutralizing GBM-expressed
chemokines that attract Treg are an additional mode for potential therapy.
However, it is important to note that since most GBM patients will be
diagnosed after Treg accumulation has begun to occur, chemokine
neutralization may not be a promising approach. Regardless, the
physiological (i.e., in vivo) potential for this therapeutic effect has to be
investigated in glioma. (Fallarino et al., 2003; Dannull et al., 2005; Ko et al.,
2005; El Andaloussi and Lesniak, 2006; El Andaloussi et al., 2006; Fecci
et al., 2006a, 2007; Jordan et al., 2008; Banissi et al., 2009; Davies et al.,
2009; Zhao et al., 2010; Mitchell et al., 2011, 2012; Pere et al., 2011; Fong
et al., 2012; Sampson et al., 2012).
cell cycle arrest with subsequent apoptosis or senescence (Naga-
sawa et al., 2012). Although TMZ is well-tolerated and has an
overall beneficial impact on patient survival, it has also been well-
described to induce immunosuppression, most often described as
various forms of lymphopenia (Lanzetta et al., 2003; Kocher et al.,
2005). The association between TMZ and lymphopenia is the pref-
erential depletion of CD4+CD25+ Treg (Su et al., 2004). Both
in human and animal studies of glioma, TMZ has been demon-
strated to alter Treg trafficking toward glioma cells, in vitro, as
well as solid tumors, in vivo. (Jordan et al., 2008; Banissi et al.,
2009; Kim et al., 2010). Clinically, TMZ appears to be beneficial
when combined with a peptide vaccine targeting the epidermal
growth factor receptor variant III (EGFRvIII) (Heimberger et al.,
2008b). Perhaps the reason this vaccine strategy worked well was
that the TMZ was administered to coincide with times points that
would target maximal Treg depletion. The strategy of combin-
ing TMZ-induced Treg depletion and vaccination is now being
in tested in ongoing phase II and III clinical trials. Since TMZ is
the current standard of care for glioma patients, manipulating the
beneficial TMZ-induced side-effect(s) holds a particular appeal in
this patient cohort.
CYCLOPHOSPHAMIDE
Cyclophosphamide, like TMZ, is also an alkylating agent that at
high doses, results in potent cytotoxicity and lymphoablation. CTX
has been used as an anti-cancer therapy since 1959. However, due
to the high cytotoxicity and side-effects, the routine use of CTX
in glioma is limited with the exception of administering continu-
ous low-doses (also called metronomic dosing). Metronomic CTX
dosing has been shown to have immunostimulatory effects that
include the expansion of antigen-specific tumor-reactive T cells, a
transient depletion of Treg and the restoration of DC homeosta-
sis (Radojcic et al., 2010). This mechanism has been suggested to
occur by the preferential depletion of CD8+ lymphoid-resident
DC, increased potency of pDC, increased migratory capacity of
DC, as well as elevated antigen presentation and cytokine secretion
(Nakahara et al., 2010). Ultimately, the metronomic CTX schedule
has been shown to result in an anti-tumor immune responses by
stimulating the effector arm of the immune response, while simul-
taneously inhibiting immunosuppression (Langroudi et al., 2010;
Sharabi et al., 2010; Zhao et al., 2010).
In a murine model of colon cancer, the combination of IL-
12 and CTX eliminates intratumoral Treg and myeloid-derived
suppressor cells, while simultaneously inducing pro-inflammatory
myeloid cells within the tumor microenvironment, an essential
component for facilitating effector T cell infiltration and subse-
quent tumor rejection (Medina-Echeverz et al., 2011). In support
of this approach, PD-1 blockade, low-dose CTX, and combina-
torial peptide administration has been shown to synergistically
induce a strong antigen-specific immune response by increasing
Tc and Tconv infiltration into the malignancy, ultimately lead-
ing to potent tumor rejection (Mkrtichyan et al., 2011). Even in
a canine model, 15 mg/m2/day of CTX leads to a decrease in the
total number and frequency of Treg in the peripheral blood, while
simultaneously increasing serum IFN-α concentrations (Burton
et al., 2011; Mitchell et al., 2012). Moreover, in 12 patients with
treatment-refractory metastatic breast cancer receiving single-
agent CTX, there was a significant initial reduction in circulating
Treg by more than 40% (p= 0.002), although this decrease was
transient, since Treg levels returned to pre-CTX treatment levels
due to increased proliferative activity (Ge et al., 2012). Moreover,
while Treg suppressor activity was maintained at normal levels, the
overall Treg depletion led to an increase in breast tumor-reactive
T cells (p= 0.03) that remained at high levels throughout treat-
ment; correlating with disease stabilization (p= 0.03) and overall
survival (p= 0.027). Depleting Treg has been attempted, clini-
cally, in several human cancers including ovarian cancer (Vermeij
et al., 2012), cervical cancer (Peng et al., 2013), renal cancer (Hui-
jts et al., 2011), melanoma (Berd et al., 1990), and glioma (Plautz
et al., 2000). However, the optimal timing of this strategy still
requires better definition with regard to anatomy and malignant
progression.
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STAT3
Signal transducer and activator of transcription 3 (STAT3) con-
trols the transcription of several genes in response to cytokines and
growth factors. IL-2, a cytokine critical for the maintenance of Treg
in vivo, contributes to Foxp3 expression in human CD4+CD25+
Tregs via STAT3 and STAT5 (Zorn et al., 2006). However, it should
be noted that while STAT3-/- progenitors show no sign of Treg
developmental block, STAT5α/β−/− lymphoid progenitors possess
a significant inhibition toward developing into thymus-derived
Treg (Yao et al., 2007). Thus, the regulation of STAT3-induced
Treg development appears to require additional co-factors (i.e.,
STAT5) for normal maturation.
STAT3 regulates the expression of TGF-β and IL-10, crucial
cytokines that contribute to the presence of tumor-associated
Treg (Kinjyo et al., 2006). Interestingly, tumor-bearing mice with
STAT3−/− hematopoietic cells possess a significant reduction in
the number of tumor-infiltrating Treg (Kortylewski et al., 2005).
Thus, developing agents that inhibit STAT3 is a rapidly emerg-
ing goal for eventually designing a new class of compounds that
inhibit Treg development, function and/or tumor-infiltration. In
the context brain metastasis arising from melanoma cells, the
novel STAT3 inhibitor, WP1066, reverses immune suppression
through the inhibition of FoxP3 induction in peripheral T cells
and down-regulation of Foxp3 expression in nTreg (Kong et al.,
2009). Based on this and other promising pre-clinical studies
demonstrating the beneficial effects of STAT3 inhibition (Bill
et al., 2010; Hatiboglu et al., 2012; Liu et al., 2013), STAT3
inhibitors are now being tested in clinical trials for advanced solid
tumors.
CD25
Several strategies have been attempted for depleting Treg based
on the constitutively expressed cell surface marker, CD25. In the
context of hematological malignancy, a phase I study using LMB-
2, a CD25 mAb conjugated to truncated Pseudomonas exotoxin,
was found to elicit a promising clinical response (Kreitman et al.,
2000). However, in the setting of metastatic melanoma, despite
inducing a transient decrease in Treg in vivo, LMB-2 administra-
tion failed to augment the immune response to cancer vaccination
and patients neither experienced an objective beneficial response
nor severe side-effect in the form of autoimmunity (Powell et al.,
2007).
The recombinant IL-2-diphtheria toxin conjugate,DAB(389)IL-
2 (also known as denileukin diftitox and ONTAK) was designed
for use as a Treg-depleting agent. However, there are mixed reports
regarding its ability to successfully deplete Treg and stimulate the
anti-tumor immune response (Attia et al., 2005a; Dannull et al.,
2005; Mahnke et al., 2007). In non-Hodgkins lymphoma patients,
although the combination of denileukin diftitox with rituximab
decreased the number of CD25+ T cells, denileukin diftitox sig-
nificantly increased the toxicity of the combination without an
improvement in response rate or time to progression (Ansell et al.,
2012).
In the setting of malignant glioma, CD25 mAb has been used
in several studies as a means to deplete Treg. In an experi-
mental model of glioma, GL261 cell-based brain tumor-bearing
mice pre-treated with CD25 mAb lived significantly longer than
those bearing tumor and receiving control IgG antibody (El
Andaloussi et al., 2006). The mechanism of action was associ-
ated with a decrease in the frequency of brain tumor-infiltrating
CD4+CD25+ T cells, while simultaneously eliminating their sup-
pressor activity. The inhibition of Treg function permits enhanced
lymphocyte proliferation and IFN-γ production with as much
as 80% lysis of glioma cells in vitro. When combined with DC
immunization, CD25 mAb elicits tumor rejection in 100% of
challenged mice (Fecci et al., 2006b). Furthermore, using GL261
cell-based brain tumor-bearing mice treated with both intraperi-
toneally and intracranially administered CD25 mAb results in
long-term survival and complete tumor rejection, when com-
pared to the systemic administration of CD25 mAb alone.
(Poirier et al., 2009). Accordingly, the depletion of Treg with
CD25 mAb strongly enhances the efficacy of DC vaccination,
although CD25 mAb had an anti-tumor effect independent of
the DC vaccination response as well (Maes et al., 2009). Impor-
tantly, DC vaccination is required to protect animal models from
intracranial tumor re-challenge, since no long-term protection
was observed in animals that had initially received CD25 mAb
alone.
Treg depletion functions differently based on immunocom-
petent and lymphopenic contexts, as well as when it is given in
relation to the overall tumor burden. Accordingly, CD25 mAb in
normal mice decreases intratumoral Treg and contributes to tumor
rejection in small tumors, but is less effective in large established
tumors and also disrupts the effector arm of the immune response
(Curtin et al., 2008). In contrast, in lymphodepleted hosts, CD25
mAb decreases Tregs without impairing effector T cell responses
(Mitchell et al., 2011). In a randomized placebo-controlled pilot
study, combinatorial administration of humanized CD25 mAb,
Daclizumab, with peptide vaccination against the EGFRvIII and
lymphodepleting TMZ safely and selectively depleted Treg in
patients with GBM (Sampson et al., 2012). Moreover, it was
reported that Daclizumab treatment was well-tolerated with no
symptoms of autoimmune toxicity and a significant decrease in
the frequency of circulating Treg when compared to saline-treated
controls.
CTLA-4
CTLA-4 is a constitutively expressed cell surface molecule on Treg.
Like its closely resembling ligand, CD28, CTLA-4 also binds to
the co-stimulatory molecules, CD80 and CD86 on APC, acting
as a powerful negative regulator of T cell activation (McCoy and
Le Gros, 1999) via the induction of indoleamine 2,3-dioxygenase
and/or TGF-β (Fallarino et al., 2003; Rudd, 2008). In both humans
and in mouse models, Treg from malignant gliomas have been
shown to express high levels of CTLA-4 (El Andaloussi and
Lesniak, 2006; El Andaloussi et al., 2006). CTLA-4 is not only
associated with glioma progression and prognosis, the CTLA-4
A49G polymorphism might also be a potential clinically relevant
biomarker for distinguishing individuals with a high risk for devel-
oping glioma (Wu et al., 2011). In a human study of DC vaccines,
it was found that monitoring the changes in Treg frequency and
dynamic expression of the negative co-stimulatory molecules on
peripheral blood T cells, before and after DC vaccination, may
predict survival (Fong et al., 2012). In the GL261 mouse model
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of glioma, combining Treg depletion with CTLA-4 neutralization
boosts glioma-specific Tc and Tconv effector T cell responses,
while also increasing anti-glioma IgG2A antibody titers; ulti-
mately resulting in complete tumor rejection (Grauer et al., 2007).
Using the same model, vaccination with granulocyte-macrophage
colony-stimulating factor (GM-CSF)-expressing whole glioma cell
vaccination followed by CTLA-4 blockade has been demonstrated
to significantly improve survival (Agarwalla et al., 2012). In the
SMA-560 mouse model of glioma, neutralization of CTLA-4 with
monoclonal antibody, 9H10, confers a long-term survival ben-
efit in 80% of treated mice with re-establishment of normal
CD4 counts concomitant with a decreased Treg fraction. Inter-
estingly, treatment benefits appeared to be primarily mediated
through the CD4+CD25− T cell population rather than the Treg
population, as CD4+CD25− T cells from treated mice showed
improved proliferative responses and resistance to Treg-mediated
suppression, whereas Treg from the same mice remained “tolero-
genic” and displayed no defect in suppressor function (Fecci et al.,
2007). Based on these and other promising pre-clinical studies,
humanized CTLA-4 mAb has now been successfully tested in clin-
ical trials for the treatment of metastatic melanoma (Mathew
et al., 2013; Wilgenhof et al., 2013). However, results from late
phase clinical trials studying the therapeutic effects of this anti-
body for treating patients with malignant glioma have yet to be
reported (Phan et al., 2003; Attia et al., 2005b; Maker et al., 2005)
and must be considered in the context of the potent neurolog-
ical side-effects that have been previously reported (Bot et al.,
2013).
GITR
Gluococorticoid-induced TNFR-related protein (GITR, also
known as TNFRSF18), a type I transmembrane protein with
homology to other TNF receptor family members such as OX40,
CD27, and 4-1BB, is normally expressed at very low levels on rest-
ing Tc, low levels on Tconv and at constitutively high levels on
Treg (Cohen et al., 2010). Currently, there are competing theo-
ries regarding the impact of the GITR-GITRL interaction on Treg.
While there is evidence to suggest that this interaction renders
responder T cells more susceptible to suppression by Treg, it has
also been shown that GITR signaling in Treg, directly, inhibits
the ability to mediate suppression of responder T cells (Shevach
and Stephens, 2006). In a mouse model of fibrosarcoma, T cell
stimulation by agonistic GITR mAb attenuated Treg-mediated
suppression and enhanced tumor-killing by Tc and Tconv cells
via increased secretion of IFN-γ. This worked synergistically with
co-administration of CTLA-4, but not with CD25 mAb (Ko et al.,
2005) reinforcing the hypothesis that while both GITR and CD25
mAb inhibit Treg-mediated suppressor activity as a primary mech-
anism of promoting tumor immunity, CTLA-4 mAb indepen-
dently contributes to tumor rejection by directly acting on effector
T cells. In the B16 cell-based mouse model of melanoma, the ago-
nist GITR mAb, DTA-1, induces regression of small established
tumors in mice. Although DTA-1 neither altered systemic Treg
frequencies nor their intrinsic suppressor activity, intratumoral
accumulation of Treg was significantly impaired, resulting in a
greater Teff:Treg ratio, thereby enhancing tumor-specific CD8+ T
cell activity (Cohen et al., 2010).
Independently, we have shown that IDO-competent brain
tumors promote tumor-infiltrating Treg to significantly upreg-
ulate the expression of GITR, when compared to IDO-deficient
tumors (Wainwright et al., 2012). Interestingly, this effect is locally
regulated since Treg in IDO-competent tumors have upregulated
levels of GITR when compared to those Treg in draining cervi-
cal lymph nodes and/or spleen. Ultimately, the overabundance
of GITR on glioma-infiltrating Treg may provide the necessary
avidity for future therapeutic antibody approaches that selectively
target intratumoral – rather than systemic – Treg inhibition. Cur-
rently, a humanized GITR mAb (TRX518), developed by Toleryx,
Inc., is in a Phase 1 safety and tolerability dose-escalation clinical
trial for late stage (III and IV) melanoma patients with unre-
sectable tumor, although this agent has not yet been investigated
for primary brain tumor patients.
OX40
OX40 (also known as CD134), another member of the TNF recep-
tor family, is expressed on naive Tregs and transiently upregu-
lated following TCR stimulation. OX40 stimulation in Treg using
agonistic antibodies inhibits the capacity to suppress, thereby
restoring effector T cell proliferation, IL-2 gene transcription
and cytokine production (Valzasina et al., 2005). Using a mouse
tumor model, it has been shown that agonistic OX40 mAb,
but not CD25 mAb, induces tumor rejection in 80% of mice.
OX40-mediated functional inactivation of Treg recruits nearby
DC, promoting the induction of an adaptive immune response
(Piconese et al., 2008). Additionally, combinatorial therapy using
CTX and OX40 mAb provides potent anti-tumor immunity result-
ing in the regression of established melanoma in a B16 cell-based
model. Within the tumor, combinatorial therapy induces a pro-
found depletion of Treg depletion accompanied by an influx of
effector T cells leading to a favorable Teff:Treg ratio (Hirschhorn-
Cymerman et al., 2009). In a brain tumor model, mice bear-
ing GL261 cell-based glioma were susceptible to the treatment
with OX40 mAb and tumor regression was dependent on the
participation of both Tc and Tconv cells (Kjaergaard et al.,
2000). Similarly, mice bearing intracranial GL261 cell-based brain
tumors and treated with a combination of OX40 mAb, local cra-
nial radiotherapy, as well as intrasplenic vaccination with DC
demonstrated the complete regression of tumor resulting in long-
term survival (≥120 days) with no evidence of tumor recurrence
and resistance to further intracranial tumor challenge (Kjaer-
gaard et al., 2005). Importantly, OX40 mAb-mediated therapy
is currently being tested in a Phase 1/2 trial for patients with
metastatic melanoma (NCT01689870), as well as in a Phase 1
trial for patients with advanced forms of cancer (NCT01644968)
although it has yet to be initiated for primary brain tumors,
specifically.
FOXP3
Targeting the constitutively expressed receptor, CD25, to neutral-
ize Treg is limited by the challenge of the transient expression on
Tc and/or Tconv during activation-induced upregulation, includ-
ing those vaccine-associated effector T cells that carry out anti-
tumor responses. As of today, Foxp3, a nuclear transcription factor
required for generating nTreg, is the only gene product known to
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be (almost) exclusively expressed by Treg in mice. Notable excep-
tions to this rule are Tr1 and Th3 CD4+ regulatory T cells that
professionally express IL-10 and TGF-β, respectively, but do not
express FoxP3.
Vaccination of mice with FoxP3 mRNA-transfected DC elicits
a robust FoxP3-specific Tc response that contributes to vaccine-
associated protective immunity. As might be implied by the more
promiscuous expression of CD25, relative to FoxP3 on or in Treg,
respectively, CD25 mAb and FoxP3 vaccination have slightly dif-
ferent effects in tumor-bearing mice. While CD25 mAb depletes
Treg systemically, FoxP3 vaccination leads to Treg depletion intra-
tumorally, with sparing of Treg in the periphery (outside of the
tumor (Nair et al., 2007). This disparity may reflect the ability
of vaccine-programed effector T cells to differentially sense aber-
rantly programed Treg, as we and others have demonstrated that
intratumoral Treg are phenotypically distinct (Gounaris et al.,
2009; Cohen et al., 2010; Wainwright et al., 2010, 2012; Blat-
ner et al., 2012), vs. the effects of an antibody that lacks such
sophistication.
Another strategy for targeting FoxP3 in Treg utilizes a syn-
thetic peptide, P60, that binds directly to FoxP3. P60 enters Treg
and inhibits FoxP3 nuclear translocation, decreasing the ability
to suppress the transcription of NF-κB and NFAT. When P60
was administered to BALB/c mice and immunized with the Tc
epitope, AH1, from CT26 tumor cells, immune-mediated protec-
tion against tumor implantation occurred (Casares et al., 2010).
Although this approach has shown some promising results, pre-
clinically, this strategy has yet to be tested in the context of patients
with cancer.
CONCLUSION
Regulatory T cells are a highly important lineage of immune
cells that maintain tolerance to self, provide regulatory stabil-
ity during the resolution of inflammation and expand as a
population during pregnancy to suppress the potential sponta-
neous T cell-mediated rejection due to paternally derived fetal
alloantigens. Although beneficial under normal circumstances,
pathological Treg responses can promote autoimmunity or malig-
nant transformation in the absence or overabundance of func-
tion/accumulation, respectively. Thus, understanding factors that
regulate Treg suppressor activity, cytokine production, homing,
expansion, contraction, induction, conversion, TCR reactivity,
and interaction with other cells is a critically relevant area of
investigation.
The level of Treg accumulation in malignant astrocytoma is
progressive; increasing with tumor grade and maximal in GBM (El
Andaloussi and Lesniak, 2006). The depletion of Treg in models of
malignant brain tumors extends survival and ameliorates disease,
depending on timing, tumor size, and dosage of the depleting
agent. Given the constitutively high expression of certain mole-
cules on the Treg cell surface (i.e., CTLA-4, GITR, and CD25),
depleting, and/or neutralizing these cells with CTLA-4-, GITR-,
and CD25-mAbs is an attractive therapeutic modality. However,
these approaches tend to have many side-effects, additional targets
(i.e., Tc and Tconv), as well as a relatively high degree of toxicity to
patients. Thus, additional approaches are needed to address these
concerns.
Recent identification of Treg in brain tumors as predomi-
nantly arising from a thymus-derived origin (Wainwright et al.,
2011) may enlighten future investigation with regard to delin-
eating antigen specificity, clonality of this cellular pool, as well
as epigenetic programing (given the high stability of nTreg rel-
ative to iTreg). If it is found that the tumor-infiltrating nTreg
are primarily clonal in nature and therefore, expand from few
Treg progenitors, antigen-specific therapies may have a higher
chance of becoming highly effective, given the smaller TCR reper-
toire that will be required to target against. However, if it is
determined that Treg in GBM arise from a more heterogenous
population, and therefore originating from a high amount of
TCR-distinct clones, then an antigen-specific therapy for depleting
Treg may be a less attractive approach, given the potentially enor-
mous amount of variation between Treg in tumors, as well as the
additional variation that may arise between individuals. Regard-
less of either outcome, the TCR repertoire in GBM-infiltrating
Treg is currently unknown and therefore an important future
research endeavor to pursue. It is equally important to keep in
mind that nTreg depletion via TCR-specific targeting may lead to
more effective tumor rejection, while simultaneously increasing
bystander damage to CNS-resident astrocytes (and any other cells
co-expressing the TCR-specific peptide/MHC II complex that the
Treg is reactive to). Theoretically, this would be due to the loss
of Treg-mediated tolerance against astrocytes. However, the over-
all risk due to the loss of dominant tolerance to a single antigen
is likely to play a minimal role in causing autoimmune pathol-
ogy, since nTreg are likely to react with many astrocyte-specific
antigens.
The recent finding that nTreg accumulation in brain tumors is
dependent on the expression of IDO represents an exciting new
direction for Treg research in neuro-oncology. IDO is an attractive
target for therapeutic consideration given its minimal expression
in normal CNS-resident neurons and glia, versus its high expres-
sion in GBM. It is important to appreciate that in vitro-cultured
GBM cells express negligible IDO levels normally (Miyazaki et al.,
2009). In contrast, the exposure of pro-inflammatory cytokines,
such as IFN-γ, rapidly induces IDO expression and tryptophan
catabolic activity in GBM cells, in vitro. However, whether this sim-
ple induction of IDO, in vitro, fully reflects the pro-tumorigenic
activity, in vivo, is doubtful, given that this enzyme also possesses
the ability to regulate downstream signaling events. Moreover, our
recent observation demonstrating IDO promoting gliomagenesis
by increasing the recruitment of Treg to brain tumors (Wainwright
et al., 2012) must be interpreted carefully. This observation was
based on the orthotopic GL261 cell-based model whereby shRNA
was used to permanently knockdown IDO expression in implanted
tumors. However, by virtue of intracranial implantation, the BBB
was temporarily disrupted at a time that inflammation was ectopi-
cally induced. This inflammation is likely to have co-induced
the upregulation of damage associated molecular pattern recep-
tors (DAMP) and downstream signaling cascades (Topfer et al.,
2011), as well as a presumed release of CNS-resident antigen to
the cervical draining lymph nodes. This collective action may
have contributed to an artificially induced anti-tumor response
that aided brain tumor rejection in the absence of IDO expres-
sion. Although we did verify a decreased level of glioma-resident
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Table 2 | Ongoing clinical trials using 1-MT as an adjuvant immunotherapy.
Title Status Identifier Goal
IDO inhibitory study for relapsed or
refractory solid tumors (D1-MT)
Terminated NCT00739609 Determine the safety and efficacy of D1-MT in patients
with recurrent or refractory solid tumors. Establish the
toxicities of D1-MT and define any dose-limiting toxicities.
D1-MT in treating patients with
metastatic or refractory solid tumors
that cannot be removed by surgery
Recruiting
patients
NCT00567931 Phase I trial to study effects and best dose of D1-MT in
treating patients with metastatic or refractory solid
tumors that cannot be removed by surgery.
D1-MT and Docetaxel in treating
patients with metastatic solid tumors
Recruiting
patients
NCT01191216 Phase I trial to study the effects and best dose for giving
D1-MT and Docetaxel together in treating patients with
metastatic solid tumors.
Vaccine therapy in treating patients
with metastatic breast cancer
Recruiting
patients
NCT01042535 Randomized Phase I/II trial to study the side-effects and
best dose of giving vaccine therapy and to assess the
effectiveness in treating patients with metastatic breast
cancer.
Study of chemotherapy in combination
with IDO inhibitor in metastatic breast
cancer
Ongoing, not
recruiting
patients
NCT01792050 To compare the effects, good and/or bad, of standard of
care therapy (Docetaxel) with or without the
co-administration of D1-MT.
Phase II study of Sipuleucel-T and
Indoximod for patients with refractory
metastatic prostate cancer
Recruiting
patients
NCT01560923 Randomized Phase II, double blind, multi-institutional
study of Indoximod or placebo after the completion of
standard of care Sipuleucel-T in men with asymptomatic
or minimally symptomatic metastatic prostate cancer
that is hormone refractory.
Treg in the GFAP:(12)V-Ha-Ras transgenic glioma model (Shan-
non et al., 2005) that was backcrossed to a globally IDO−/−
background, this did not distinguish the contribution of glioma-
expressed- and peripherally expressed-IDO to CNS-resident Treg.
To better understand the role of IDO in brain tumors under
normal conditions, we have now created a transgenic model of
glioma that is selectively deficient for IDO only in cells capa-
ble of forming astrocytoma by backcrossing a tamoxifen-induced
GFAP-Cre driven high grade astrocytoma mouse model (Chow
et al., 2011) with floxed IDO mice. This new mouse model
will allow us to study the contributions of tumor-derived ver-
sus peripheral sources of IDO with regard to Treg recruitment,
the anti-tumor immune response, as well as overall impact on
survival.
Aside from IDO1, IDO2, and TDO are also tryptophan cata-
bolic molecules co-expressed by glioma. Coincidently, the upreg-
ulation of TDO in glioma is strongly associated with decreased
overall survival in patients (Opitz et al., 2011). However, the roles
of IDO2 and TDO in the regulation of Treg recruitment to glioma
has yet to be investigated. It is interesting that clinical trials cur-
rently investigating IDO inhibitors as an adjuvant immunotherapy
are currently utilizing D1-MT (Table 2), which inhibits IDO2,
rather than IDO1 (Lob et al., 2009). However, this finding is
controversial, since a separate study found that L1-MT, rather than
D1-MT, is a better inhibitor of IDO2 tryptophan catabolic activ-
ity (Qian et al., 2012). Regardless, it was also shown that even
in the presence of a high concentration of 1-MT, IDO2-induced
T cell proliferative growth arrest could not be inhibited. Collec-
tively, these data suggest that, in addition to IDO1, IDO2 and TDO
may also be high-impact targets for investigating their contribu-
tion to modulating Treg levels, as well as overall future therapeutic
possibilities for glioma patients.
In summary, we highlight Treg as critical cells involved in
suppressing the anti-glioma immune response. This mecha-
nism involves the co-inhibitory ligand CTLA-4, is therapeutically
modulated with Treg-depleting CD25 mAb and Treg function-
modulating GITR agonistic mAb. We also highlight the trypto-
phan catabolizing enzyme, IDO1, as a critical modulator of Treg
recruitment and/or expansion to/within the glioma, as well as raise
the possibility that enzymes with similar catabolic activity, IDO2
and TDO, may be attractive future targets for immunotherapeutic
consideration. With these insights in mind, Treg immunomodu-
lation as a means to increase GBM immunogenicity appears to be
a rapidly developing approach.
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